motajmsc Profile Banner
Jose Mauricio Mota Profile
Jose Mauricio Mota

@motajmsc

Followers
462
Following
5K
Statuses
442

Medical Oncologist MD, PhD @rededor; Chief, GU Med Onc Service @icesp_; former clinical fellow @mskcc. Views=my own. RTs≠endorsements. #GU_Oncology

Sao Paulo, Brazil
Joined January 2012
Don't wanna be here? Send us removal request.
@motajmsc
Jose Mauricio Mota
5 days
RT @yasserged: Our paper on IO combinations in metastatic translocation RCC is now online. Great collaborative work and addition to treatme…
0
13
0
@motajmsc
Jose Mauricio Mota
5 days
0
0
1
@motajmsc
Jose Mauricio Mota
3 months
RT @CSuartz: Is it safe to perform robotic cystectomy in patients with previous pelvic radiation exposure? What is the current evidence on…
0
6
0
@motajmsc
Jose Mauricio Mota
3 months
Fantastic work by Dr. Felippe Lazar - very proud of him. It has been my pleasure to work together with Felippe to create and improve cancertrials_BR platform.
@felippelazar
Felippe Lazar
3 months
👉🏼 Finding available cancer trials in Brazil is a thought task and most hem-oncs will end up asking friends. I recently began an open and collaborative data project of showcasing these trials built on top of the clinicaltrialsGov database - 1/n
0
1
4
@motajmsc
Jose Mauricio Mota
3 months
RT @felippelazar: 👉🏼 Finding available cancer trials in Brazil is a thought task and most hem-oncs will end up asking friends. I recently…
0
8
0
@motajmsc
Jose Mauricio Mota
7 months
RT @mishabeltran: Check out our new review in @NatRevUrol on biologic determinants of PSMA expression, regulation, and heterogeneity in pro…
0
67
0
@motajmsc
Jose Mauricio Mota
8 months
RT @CSuartz: We published last month the 15-year series of the Cancer Institute of the State of São Paulo with 39 patients presenting prima…
0
3
0
@motajmsc
Jose Mauricio Mota
9 months
RT @CalaisJeremie: We can do better than a fixed set of 6 cycles of LuPSMA at a 6-week time interval ! Great multicenter data of >100 pati…
0
14
0
@motajmsc
Jose Mauricio Mota
10 months
RT @paulosiqamaral: Congrats to @Icesp_ fellows for achieving for the 3rd year in a row ASCO-ITE highest score! Proud of you all! @ASCO 🇧🇷…
0
4
0
@motajmsc
Jose Mauricio Mota
10 months
RT @DrChoueiri: The @US_FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive sol…
0
13
0
@motajmsc
Jose Mauricio Mota
11 months
RT @CSuartz: COBRA score can be a useful prognostic tool for which urothelial variants after a radical cystectomy ? @motajmsc @Urologia_USP
0
3
0
@motajmsc
Jose Mauricio Mota
11 months
RT @Uromigos: EV and pembrolizumab doubling PFS and OS in 1st line UC compared to chemotherapy @NEJM
Tweet media one
0
56
0
@motajmsc
Jose Mauricio Mota
1 year
RT @CSuartz: Key messages from our new study: 1) Use the site of your camera to associate the omphaloplasty 2) Take care in tumor manipulat…
0
4
0
@motajmsc
Jose Mauricio Mota
1 year
RT @brian_rini: Updated table of IO combos (ITT population) in front line mRCC after #ASCOGU24. Has anything changed for you based on these…
0
81
0
@motajmsc
Jose Mauricio Mota
1 year
RT @PortalOnconews: O oncologista José Mauricio Mota, chefe do grupo de tumores geniturinários do ICESP/FMUSP e Oncologia D’Or, é coautor d…
0
1
0
@motajmsc
Jose Mauricio Mota
1 year
RT @apolo_andrea: Brief summary of the AMBASSADOR study @OncoAlert @OncBrothers @bergsa83 @morr316 @PGrivasMDPhD @B
0
34
0
@motajmsc
Jose Mauricio Mota
1 year
RT @crisbergerot: Big thanks to @ASCO for featuring our presentation at #GU24 in the @ASCO Daily News! Grateful for the opportunity to pre…
0
24
0